Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year

Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year Robert Meehan, M.D., appointed as Chief Medical Officer, bringing extensive clinical development expertise to advance the Company’s radiotherapeutic pipeline BOSTON, Mass. and VANCOUVER, British Columbia, December 4, 2025 – Alpha-9 Oncology, […] The post Phase 1 study advances A9-3408, an Actinium-225-based radiotherapeutic, building on the progress of the company’s imaging agent, A9-3202, which entered the clinic last year